Jacobs Receives Contract for Biotechnology Project

Jacobs Engineering Group Inc. have received a contract from Biogen Idec to provide engineering, procurement, validation, and site support services for the first cell culture manufacturing facility at the greenfield biotechnology plant in Hillerod, Denmark. The manufacturing facility is expected to produce TYSABRI® (natalizumab), which is used in the treatment of multiple sclerosis. The plant is scheduled to be completed in 2009.

Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. The company creates new standards of care in therapeutic areas with high unmet medical needs and has significant products serving patients in more than 90 countries. This will be their first manufacturing facility in Europe. Jacobs performed conceptual design for the facility and will execute this new scope of work from their office in Reading, England.

Find out more about  Jacobs

Search for more Jacobs News

Posted 16/05/07

Back